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1  |  INTRODUCTION
Electronic cigarettes (E‐cigarettes) are hand‐held electronic 
devices that generate vapours or aerosols from E‐cigarette 
liquid (E‐liquid) without combustion. The main components 
of E‐liquid are humectants (ie, propylene glycol, vegetable 
glycerol), nicotine and flavourings. The main compartments 
of an E‐cigarette comprise a mouthpiece, a cartridge, a 
heating element/atomizer and a battery (Figure 1). E‐liquid 
is stored in the cartridge and then supplied to the atomizer 
which contains a small coil of electrically resistant wire that 
heats up when the battery is switched on.
Electronic cigarettes have gained rapidly in popularity 
around the world in recent years; sales of E‐cigarette may 
even surpass conventional cigarettes by 2023.1 Since E‐cig-
arettes were invented in 2003, overall usage increased from 
3.3% to 8.5% between 2010 and 2013 amongst adults in the 
USA2 and the experience of E‐cigarette usage rose from 4.6% 
to 8.2% in 2014 amongst young people aged 11‐18 in the 
UK.3 In addition, a rapid rise in E‐cigarette use has occurred 
not only amongst current smokers, but also non‐smokers 
who may therefore develop a smoking habit and/or nicotine 
addiction.4
Public Health England promoted the use of E‐cigarettes as 
smoking cessation aids, which could be contributing to at least 
20 000 successful new quits per year, and many E‐cigarette 
smokers believe this to be a benefit of E‐cigarettes.5 Long‐term 
E‐cigarette use can assist those tobacco smokers who attempt 
to quit smoking to reduce cigarette smoke (CS) consumption, 
without severe withdrawal symptoms.6 The increased preva-
lence of E‐cigarette usage is positively correlated to success in 
quitting cigarette smoking.7 Evidence also shows that E‐ciga-
rette use helps smokers to commit to smoking cessation, thus 
leading to fewer smoking‐related diseases.8,9
In addition to promoting abstinence from smoking, E‐
cigarettes may help those who cannot totally quit smok-
ing to reduce their exposure to tobacco‐specific toxicants. 
Manufacturers also promote E‐cigarettes as a safe alternative 
to conventional cigarettes due to lower levels of carcinogens 
and toxicants in vapours.10 These recommendations were 
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Abstract
Electronic cigarettes (E‐cigarettes) are considered a preferable alternative to conven-
tional cigarettes due to the lack of combustion and the absence of tobacco‐specific 
toxicants. E‐cigarettes have rapidly gained in popularity in recent years amongst both 
existing smokers and previous non‐smokers. However, a growing literature demon-
strates that E‐cigarettes are not as safe as generally believed. Here, we discuss the 
immunological, and other, deleterious effects of E‐cigarettes on a variety of cell 
types and host defence mechanisms in humans and in murine models. We review not 
only the effects of complete E‐cigarette liquids, but also each of the main compo-
nents—nicotine, humectants and flavourings. This MiniReview thus highlights the 
possible role of E‐cigarettes in the pathogenesis of disease and raises awareness of 
the potential harm that E‐cigarettes may cause.
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supported by The Royal College of Physicians in the UK. 
The most common reasons given for the use of E‐cigarettes 
amongst pregnant women were the perception of less harm 
than CS and help with smoking cessation. An online survey 
demonstrated that the majority of the respondents believed 
that E‐cigarettes are less harmful than tobacco smoking and 
that they have few side effects, with less coughing and better 
breathing.11 Furthermore, E‐cigarette users had positive atti-
tudes towards E‐cigarettes as they regarded the ingredients to 
be less harmful than CS, although this judgement was based 
on incomplete information and knowledge.12
The World Health Organization (WHO) does not recom-
mend the use of E‐cigarettes for never smokers, children and 
pregnant women13 and strongly advises consumers not to 
use E‐cigarettes until a reputable regulatory body has found 
them to be safe.14 The sale of E‐cigarettes is already banned 
in 25 of 68 countries that regulate them,15 and the US Food 
and Drug Administration (FDA) has proposed a range of 
regulatory tools to prohibit flavoured E‐cigarettes recently.16 
Moreover, despite the positive claims of manufacturers and 
the perceptions of the public, the use of E‐cigarettes remains 
controversial, and a growing literature provides evidence for 
deleterious effects of E‐cigarettes. Here, we discuss the im-
munological, and other, effects of E‐cigarette on a variety of 
cell types in humans and in murine models, discussing both 
complete E‐liquids and their main constituents (Figure 2). 
This MiniReview might help the public to consider whether 
to use E‐cigarettes based on scientific evidence.
2 |  EFFECTS OF E‐CIGARETTES 
IN HUMANS
2.1 | Benefits of E‐cigarette use
Users of conventional cigarettes who switched to E‐ciga-
rettes reported reduced nicotine withdrawal symptoms with 
less cigarette craving and improved chest tightness and other 
health effects over the course of 2 weeks.17 Substitution of 
cigarettes by nicotine‐containing E‐cigarettes also reduced 
the exposure to carcinogens and toxicants commonly found 
in CS, assessed by urine biomarkers for tobacco‐specific 
nitrosamine, volatile organic compounds and polycyclic 
aromatic hydrocarbons. A one‐year, randomized, controlled 
trial of CS smokers, who completely stopped smoking or 
switched to E‐cigarette use, showed progressive improve-
ments in respiratory symptoms, particularly coughing and 
shortness of breath.18 A 1‐year prospective, randomized con-
trol study found restoration of “fractional nitric oxide concen-
tration in exhaled breath” (FeNO) and reduction in “exhaled 
carbon dioxide” (eCO) in CS users who completely stopped 
cigarette smoking after switching to E‐cigarettes, along with 
improvements in symptom scores.19 Nitric oxide is involved 
in antimicrobial activity against lung pathogens and has anti‐
tumour effects, whereas eCO is a biomarker of smoking that 
reflects airway inflammation; thus, normalization of FeNO 
and eCO might support the use of E‐cigarettes to reverse 
the harmful effects of CS in the lungs. A prospective 3.5‐
year observational study of nine E‐cigarette users who never 
smoked conventional cigarettes found E‐cigarette use did not 
alter healthy outcome including blood pressure, heart rate, 
body‐weight, lung function, respiratory symptoms, exhaled 
breath nitric oxide (eNO), exhaled carbon monoxide (eCO) 
or high‐resolution computed tomography of the lungs.20
In addition to helping to reduce harmful effects in smokers 
with normal lung function, E‐cigarette use may also benefit pa-
tients with respiratory and systemic diseases. COPD patients 
who switched to the use of E‐cigarettes reduced their CS con-
sumption, and more than half stopped cigarette smoking com-
pletely during a 12‐month follow‐up.21 They also had significant 
reduction in annual COPD exacerbation, rate of FEV1 decline 
and improved symptoms and ability to perform daily physical 
activities. Similarly, a marked attenuation in CS consumption 
was found in asthma patients who switched to E‐cigarettes, with 
better asthma control, lung function and lower airway hyper‐
responsiveness over a 2‐year period.22 Regular E‐cigarette use 
could help reduce CS consumption in arterial hypertensive pa-
tients, further showing good blood pressure control and disease 
severity after 12 months' follow‐up.23
2.2 | Effects of E‐cigarettes 
on the oral cavity
Nicotine has been demonstrated to alter the cytoskeleton24 
and to induce extracellular matrix remodelling25 in gingival 
F I G U R E  1  Structure of a second‐
generation electronic cigarette
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F I G U R E  2  Effects of electronic cigarettes in humans
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fibroblasts—a cell type that is directly exposed to CS con-
stituents during smoking (Table 1). CS inhibited metabolic 
ability of human gingival fibroblasts time‐dependently, as as-
sessed by MTT assay.26 Exposure of human gingival fibro-
blasts to E‐liquid, with and without nicotine, reduced their 
metabolic activity in a dose‐ and time‐dependent manner.27 
E‐liquid with nicotine concentrations of greater than 1 mg/mL 
showed pronounced toxicity that was further exacerbated by 
vaporizing the fluid. Consistent with the study treating human 
gingival fibroblasts, both CSE and E‐cigarette vapour extract 
(ECVE) altered morphology, proliferation rate, apoptosis, mi-
gration and wound closure.28 Of note, CSE and ECVE with 
nicotine exert greater magnitude of damage than those with-
out nicotine. It has been reported that CS triggered the produc-
tion of reactive oxygen species (ROS) from human gingival 
fibroblasts.29 Similarly, ROS production was increased sig-
nificantly after 24‐hour exposure of gingival fibroblasts to 
either nicotine‐containing or nicotine‐free fluids and vapours, 
indicating that nicotine was not the only inducer of ROS pro-
duction.27 Levels of the pro‐apoptotic protein Bax, which is 
involved in triggering ROS production, is up‐regulated by 
CSE.30 Bax expression was also elevated after exposure to 
nicotine‐containing and nicotine‐free E‐liquids and vapours 
for 24 hours, followed by cell apoptosis after 48 hours.27
The epithelium forms the first line of defence against 
toxic substances and periodontal pathogens. CS induced 
human gingival epithelial cell apoptosis, which was con-
firmed by up‐regulated expression of Bax and caspase‐3 
activity. CS also inhibited gingival epithelial cell migration, 
which reduced the percentage of healing in a scratch assay. 
In addition, CS reduced the numbers of epithelial cell lay-
ers, resulting in epithelial disorganization.31 Exposure of 
primary human gingival epithelial cells to ECV raised levels 
of apoptosis associated with increased caspase‐3 activity ac-
companied by morphological changes and increased lactate 
dehydrogenase (LDH) activity.32
2.3 | Effects of E‐cigarettes on the 
respiratory system
After the oral cavity, airway epithelium is the next site of con-
tact with inhaled substances and serves as an active contribu-
tor in defence of the respiratory system (Table 2). Damage 
to, or alteration of, airway epithelial cells by inhaled particles 
can increase the permeability of the epithelium, leading to 
inflammatory cell influx into the airways. These infiltrating 
cells contribute to persistent inflammation and the secretion 
of mediators that cause lung tissue destruction, including 
defensins, elastase and matrix metalloproteinases (MMPs). 
Epithelial cells themselves, through production of these me-
diators, can also participate in the destructive processes.
Several studies have compared the effects of the constitu-
ents of E‐cigarettes and tobacco on cells of the human respira-
tory tract, using either primary cells or cell lines. In one study 
using primary human bronchial epithelial cells (HBECs) ob-
tained at surgery, exposure of the cultured cells to either ECV 
or CS at an air‐liquid interface caused reduced cell viability 
and increased oxidative stress.33 These effects were seen using 
ECV with or without nicotine; indeed, similar deleterious ef-
fects were induced by the humectants alone (ie, propylene gly-
col and glycerol) that are used in the E‐liquids. However, the 
increase in cell death and oxidative stress of the HBECs was 
much more pronounced when exposed to CS than to ECV. In 
contrast, another study observed CSE induced apoptosis and 
necrosis in HBECs assessed by increasing caspase 3/7 activ-
ity and reducing viable cell protease activities, and disrupted 
cellular redox haemostasis characterized by reduction in glu-
tathione ratio and increase in intracellular ROS. However, 
nicotine‐containing ECVE did not elicit those effects.34
Another study also investigated the exposure of primary 
HBECs to ECV and CS at an air‐liquid interface, using gene‐
expression profiling as the read‐out.35 Genes up‐regulated by 
both CS and ECV were related to apoptosis, xenobiotic stress 
and oxidative stress. In addition, CS and ECV down‐regu-
lated the expression of genes associated with the assembly 
and movement of cilia, which might cause a reduction of cil-
iated cells in airway epithelium and compromise mucociliary 
clearance function—this could contribute to chronic inflam-
mation in the airways. ECV containing nicotine had more 
pronounced effects than those without nicotine. This study 
showed that ECV could induce similar effects to CS; again, 
however, the effects of CS were more pronounced.
T A B L E  1  The effects of CS and E‐cigarette on oral cavity
Effects CS E‐cigarette
Gingival fibroblast
Metabolic activity Decrease26 Decrease27
Alteration in 
morphology
Yes28 Yes28
Proliferation rate Decrease28 Decrease28
Apoptosis Increase28,30 Increase27,28
Cell migration Decrease28 Decrease28
Wound closure rate Decrease28 Decrease28
ROS production Increase29 Increase27
Pro‐apoptotic protein 
Bax expression
Increase30 Increase27
Gingival epithelial cell
Apoptosis Increase31 Increase32
Caspase‐3 activity Increase31 Increase32
Alteration in 
morphology
Yes31 (disorganization 
of epithelium)
Yes32
Lactate dehydrogenase 
(LDH) activity
N/A Increase32
CS: cigarette smoke; E‐cigarette: electronic cigarette.
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Human cell lines derived from lung epithelium (A549) 
and skin keratinocytes (HaCaT) have also been used to study 
the effects of CS, ECV containing nicotine and/or balsamic 
flavouring, and ECV humectants alone.36 CS and, to a lesser 
extent, ECV containing balsamic flavouring or nicotine trig-
gered morphological changes, elevated LDH release and re-
duced viability in both cell types. The influence of flavouring 
was greater than nicotine and the ECV humectants alone did 
not have these effects. However, exposure to the humectants 
did induce release of multiple cytokines by the lung epithelial 
cells. This paper concluded that ECV was less cytotoxic than 
CS and that the deleterious effects of E‐cigarettes were more 
related to the flavourings than to nicotine. A study examining 
the effects of CS and ECV on the HBEC cell line BEAS‐2B 
also concluded that the deleterious effects of E‐cigarettes 
were less severe than those of CS.37
Electronic cigarette vapour extract also significantly in-
creased LDH release from bronchial epithelial cells (BECs) 
in both healthy and COPD patients and induced production of 
cytokines, including interleukin (IL)‐6 and IL‐8. Moreover, 
both CS and ECVE exposure to BECs from COPD patients 
showed much lower IL‐6, CXCL10 and CCL5 production 
than those from healthy donors after Poly I:C stimulation. 
Due to the role in antiviral responses by recruiting and ac-
tivating lymphocytes, suppression of CXCL10 and CCL5 
could reduce antiviral activity in bronchial epithelium, lead-
ing to elevated susceptibility to infection.38
Surfactant helps to reduce surface tension of alveolar 
fluid; therefore, less energy is required to inflate the lungs 
and prevent alveolar collapse. High surface tension is a 
known characteristic of asthma, pneumonia and COPD. Both 
CS and ECVs affected surfactant microstructure analysed by 
Infasurf®, a calf lung surfactant extract used as a lung surfac-
tant model. However, surface tension was increased by CS 
but not ECVs. Interestingly, tar was the only component in 
CS able to increase surface tension, suggesting E‐cigarette 
did not alter surface tension due to lack of tar.39
Experiments with the human lung fibroblast line, HFL‐1, 
showed that these cells, like lung epithelial cells, are sensi-
tive to ECV. Again, however, the cells were more sensitive to 
CS than to ECV in the sense that CS, but not ECV, reduced 
the fibroblast viability in relatively large culture volumes, 
whereas ECV did reduce the viability only of smaller cul-
tures.40 Certain flavours of ECV, as well as CS, also induced 
IL‐6 and IL‐8 production.40,41 Acute increase in mitochon-
drial ROS was also observed in the human lung fibroblast cell 
line treated with nicotine‐containing ECVs,41 consistent with 
findings using CS.42
Electronic cigarette vapour condensate (ECVC) caused 
more reduced viability of alveolar macrophages than E‐liq-
uid.43 ECVC also induced apoptosis, necrosis, ROS pro-
duction and pro‐inflammatory cytokines (ie IL‐6, TNF‐α, 
IL‐8), chemokine MCP‐1 and proteolytic enzyme MMP‐9 
T A B L E  2  The effects of CS and E‐cigarette on respiratory system
Effects CS E‐cigarette
Bronchial epithelial cells
Cell viability Decrease33 Decrease33
Oxidative stress Increase33,34 Increase33 
No34
Apoptosis Increase34 No34
Necrosis Increase34 No34
Caspase 3/7 activity Increase No34
Glutathione ratio Increase34 No34
Alteration in gene expression Yes35 Yes35
LDH release No38 Increase38
Cytokine production (ie IL‐6, 
CXCL10 and CCL5) after Poly 
I:C stimulation
Decrease38 Decrease38
Lung epithelial cells
Morphological changes Yes36 Yes36
LDH release Increase36 Increase36
Cell viability Decrease36,37 Decrease36 
No37
Oxidative stress Increase37 No37
Inflammatory mediator 
production (ie IL‐8, MCP‐1  
and GRO‐α)
Decrease37 No37
IL‐6 production Increase37 Increase37
Surfactant
Alteration in microstructure Yes39 Yes39
Surface tension Yes39 Yes39
Lung fibroblasts
Cell viability Decrease40 Decrease40
Inflammatory mediator 
production (ie IL‐6 and IL‐8)
Increase40 Increase40,41
Mitochondrial ROS production Increase42 Increase41
Alveolar macrophage
Apoptosis/necrosis Increase44 Increase43
Inflammatory mediator 
production
Increase45-47 Increase43
ROS production Increase48 Increase43
Phagocytic function Decrease46 Decrease43
Human models
Peripheral airway flow  
resistance
Increase49 Increase51
FeNO level Decrease49 Decrease51,55
Bronchitic symptoms Increase50 Increase52
Alteration in transcriptomes/
protein expression
Yes54 Yes53,54
Resonant frequency N/A Increase55
CS: cigarette smoke; E‐cigarette: electronic cigarette; FeNO: fractional exhaled 
nitric oxide; IL: interleukin; LDH: lactate dehydrogenase; ROS: reactive oxygen 
species.
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production but decrease phagocytic function of alveolar mac-
rophages, and these impacts were ameliorated by antioxidant, 
suggesting the role of oxidative stress in E‐cigarette. Similar 
to ECV, CS also has been reported to trigger the apoptosis,44 
inflammatory mediators45-47 and ROS48 but attenuate phago-
cytosis of alveolar macrophages.
Cigarette smoke is known to have deleterious effects on 
the respiratory system in humans49,50 and studies in human 
subjects also raised concerns over the safety of E‐cigarette 
use. Healthy smokers, who used E‐cigarettes for 5 minutes, 
had increased levels of peripheral airway flow resistance and 
oxidative stress illustrated by lower fractional exhaled nitric 
oxide (FeNO), demonstrating the rapid side effects of E‐ciga-
rettes.51 Adolescents using E‐cigarettes for 12 months showed 
a twofold increase in rates of chronic bronchitic symptoms, 
such as chronic cough, phlegm or bronchitis.52 Acute E‐cig-
arette use (regardless of nicotine content) by never‐smokers 
altered transcriptomes in small airway epithelium including 
downstream targets of p53 signalling related to apoptosis, cell 
cycle arrest and DNA damage.53 Moreover, E‐cigarette use 
changed transcriptomes in alveolar macrophages, thereby in-
hibiting their migration and phagocytic ability but increased 
susceptibility of E‐cigarette users to infection.53 Both chronic 
CS and E‐cigarette users had more erythematous and irritable 
airway mucosa, and there were approximately 200 proteins 
altered (78 proteins altered in both groups and 113 specif-
ically altered in vapers) in bronchial epithelium, including 
mucin MUC5AC that facilitates mucus secretion. Of note, 
some proteins up‐regulated in vapers like MUC5AC, CYP1B 
(generates covalent adducts to damage DNA) and STIM1 
(controls Ca2+ homeostasis) were also elevated by aerosol-
ized PG/VG in HBECs in vitro.54 Aside from direct use, a 
30‐minute passive exposure to E‐cigarette vapour in healthy 
non‐smokers caused small airway irritation and inflamma-
tion detected by increased resonant frequency and reduced 
FeNO, raising the possibility of potential risk to humans ex-
posed to ECV in public places and environments.55
Overall, the studies considered here indicate that ECV is 
less deleterious to the respiratory system than CS, but still 
has significant toxic and inflammatory effects whose long‐
term consequences are currently unknown.
2.4 | Effects of E‐cigarettes on other 
cells and tissues systemically
Inhaled substances can be absorbed into the bloodstream and 
distributed systemically (Table 3). It is therefore important to 
consider possible effects of ECV constituents on other cells 
and tissues in addition to effects on cells of the respiratory 
tract.
Neutrophils are an important component of innate im-
munity that act rapidly against invading pathogens by 
phagocytosis, degranulation and release of neutrophil 
extracellular traps. They are abundant in the circulation and 
migrate to sites of infection in response to chemokines and 
other chemo‐attractants. Neutrophils also release cytokines 
which can recruit and activate other cells during inflamma-
tion. Neutrophils treated with ECV extract for up to 6 hours 
showed increased expression of the neutrophil activation 
markers CD11b and CD66b56; this is in contrast with a 
report that CD11b was up‐regulated in circulating neutro-
phils from tobacco smokers only with COPD, not from to-
bacco smokers with normal lung function.57 Also, the levels 
of neutrophil elastase, MMP‐9 and IL‐8 showed similar 
changes, accompanied by p38 MAPK activation without a 
reduction in neutrophil viability. CD66b cross‐linkage be-
tween neutrophils was increased by ECV extract, which 
T A B L E  3  The effects of CS and E‐cigarette on other cells and 
tissue systemically
Effect CS E‐cigarette
Neutrophils
Activation marker (ie 
CD11b and CD66b)
No57 Increase56
Inflammatory mediator 
production
Increase56 Increase56
p38 MAPK activation N/A Increase56
Neutrophilic enzyme Increase58 Increase58
NET formation Increase58 Increase58
Cell number Increase58 No58
Cardiovascular system
Sympathetic predominance N/A Yes59
Oxidative stress Increase61 Increase59,61
Endothelial progenitor cells Increase60 Increase60
Flow‐mediated dilation Decrease61 Decrease61
Antioxidant vitamin E Decrease61 Decrease61
Umbilical vein endothelial cells
Cell viability Decrease62 Decrease62
Metabolic activity Decrease62 Decrease62
Complement deposition Increase62 Increase62
Migration Decrease63 No63
Myocardial cells
Cell death Increase64 Increase64
Morphological changes Yes64 No64
Kupffer cells
Cell viability Decrease65 Decrease65
Cell density Decrease65 Decrease65
Complement deposition Increase65 Increase65
Oxidative stress Increase65 Increase65
Inflammatory mediator 
production
Increase65 Increase65
CS: cigarette smoke; E‐cigarette: electronic cigarette.
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might cause the secretion of IL‐8. Neutrophil granulocytes 
possess two mechanisms for antimicrobial activity: degran-
ulation of stored mediators and release of NETs. The levels 
of neutrophilic enzymes associated with chronic lung dis-
eases, such as neutrophil elastase, myeloperoxidase and ma-
trix metalloproteinase‐9 and NET formation, were elevated 
in sputum derived from both CS and E‐cigarette users, with 
increasing neutrophil count by CS only.58 In addition, E‐cig-
arettes suppressed antimicrobial activity and viscoelastic 
properties of the mucus barrier, as demonstrated by decreas-
ing innate defence proteins secreted by the airway epithe-
lium. Interestingly, these proteins were elevated in tobacco 
smokers. Increased total mucin concentration, an important 
parameter for failed mucus transport in muco‐obstructive 
disease and COPD, was shown in both CS and E‐cigarette 
users. These results suggested ECV might affect neutro-
philic response and defence proteins in lungs in a similar 
way to that seen in CS users.
Habitual E‐cigarette users had a shift in cardiac auto-
nomic balance towards sympathetic predominance and 
higher systemic oxidative stress levels, which are known 
risks for cardiovascular disease (CVD).59 The levels of 
endothelial progenitor cells, the biomarker for endothelial 
function and risk marker for CVD based on their function 
in maintenance, differentiation and regeneration of endo-
thelial cells following vascular injury or necrosis, were el-
evated in participants exposed to ECV acutely, similar to 
exposure to CS.60 Flow‐mediated dilation, the other marker 
for endothelial function and CVD, was decreased after CS 
and E‐cigarette use.61 Markers of oxidative stress were el-
evated, but antioxidant vitamin E was suppressed by both 
acute CS and E‐cigarette exposure.61 Viability and met-
abolic activity of human umbilical vein endothelial cells 
(HUVECs) was inhibited by CSE and nicotine‐containing 
ECVE but not pure nicotine.62 Furthermore, the deposition 
of C1q and C5b‐9, C3b and the expression of the receptors 
for C1q onto endothelial cells was enhanced by CSE and 
nicotine‐containing ECVE while C4d were increased by 
CSE only. Since complement deposition onto endothelial 
cells is known to promote CVD progression, both CS and E‐
cigarette may increase the risk of CVD. Inhibition of endo-
thelial cell migration is a mechanistic link between CS and 
CVD. CS suppressed HUVEC migration dose‐dependently 
but ECVE did not exert this effect.63 The abundance of oxi-
dants and free radicals in CS can lead to oxidative damage, 
apoptosis and necrosis in endothelium, and this paper, in 
contrast, proposed that E‐cigarette use may reduce the risk 
of CVD by reducing exposure to oxidant species in users.63 
Myocardial cells are another example of cells in which 
oxidative stress is induced by CS. A rat myocardial cell 
line exposed to CS extract suffered large‐scale cell death 
and morphological changes; by contrast, ECV extract pro-
duced from only a minority of brands of E‐cigarette caused 
significant cell death, especially those with tobacco fla-
vouring, raising the possibility that several tobacco impu-
rities may be present in these E‐liquids.64 Indeed, nicotine 
and humectants alone did not induce cytotoxicity, suggest-
ing that flavourings and other components in E‐cigarettes 
play a significant role in causing harm (see below).
Kupffer cells are liver‐resident macrophages that locate to 
the liver sinusoids. They clear foreign substances by adher-
ing to platelets, which then return to the systemic circulation. 
Some studies indicate that liver inflammation might cause 
alterations in the circulation, leading to the development of 
systemic diseases. Exposure of immortalized rat Kupffer 
cells to CS, ECV extract or nicotine significantly decreased 
cell viability and density.65 The deposition of complement 
proteins C1q, C4d, C3b and C5b‐9 on the Kupffer cells was 
augmented by ECVE, CS and nicotine. As C5b‐9 is the main 
lytic moiety of the complement cascade, the authors hypothe-
sized that increased C5b‐9 deposition on Kupffer cells might 
be one reason for the reduction of Kupffer cell viability. 
Elevated expression of C1q receptors (C1qR) on Kupffer cells 
was also observed. No significant differences were observed 
between the effects of CS and ECV extract or various con-
centrations of nicotine in ECV extract. In addition, although 
nicotine alone was detrimental to these cells, E‐cigarettes fur-
ther enhanced the effects, suggesting that other components 
in E‐cigarettes initiate inflammatory responses. ECVE also 
induced ROS and pro‐inflammatory cytokine secretion by 
the Kupffer cells.
2.5 | Inflammatory effects of E‐cigarettes in 
murine models in vivo
Increased airborne levels of nicotine and cotinine in homes 
of E‐cigarette users are associated with passive exposure 
to ECVs (Figure 3 and Table 4).17 Children may absorb 
higher amounts of ECV constituents than adults because of 
their higher respiratory rates and increased dermal absorp-
tion; in addition, they have diminished nicotine clearance.18 
Murine experiments have therefore been performed to better 
understand the potential effects of ECV constituents in the 
young. Newborn mice exposed to ECV containing nicotine 
for 10 days after birth had significantly lower body‐weight, 
and there was a positive correlation between reduction of 
body‐weight and plasma cotinine levels.66 Nicotine‐contain-
ing ECV also attenuated alveolar growth in neonatal mice, 
assessed by a significant reduction in expression of the cell 
proliferation marker Ki67.66 Exposure of mice to CS has 
also been reported to lead to reduced body‐weight67 and lung 
development.68
Acute lung injury and greater IL‐6 secretion were ob-
served in adult mice after 3 days of CS exposure and, to a 
lesser extent, after ECV exposure.69 On the other hand, only 
CS (and not ECV) induced oxidative stress and secretion of 
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IL‐1β and TNF‐α, indicating less toxicity of E‐cigarettes.69 
In other studies, mice treated with tobacco‐flavoured ECVs 
for 3 days were observed to have significantly elevated levels 
of IL‐6, MCP‐1, IL‐1α and IL‐13 in bronchoalveolar lavage 
fluid (BALF),40 and pentraxin‐3 was elevated in mice exposed 
to ECV over a period of 4 weeks.70 These data demonstrate 
F I G U R E  3  Effects of electronic 
cigarettes in murine models
Effect CS E‐cigarette
Body‐weight Lower67 Lower66
Alveolar/lung growth Decrease68 Decrease66
IL‐6 production Increase69,72 Increase69
IL‐1β production Increase69,76 No69
TNF‐α production Increase69,73,74 No69
Oxidative stress Increase69 No69
Other inflammatory mediators in BALF/Lung Increase73,74 Increase40,70,71
Respiratory resistance Increase72 Increase71
Alveolar space enlargement Increase73,74 Increase71
Enzyme production (ie protease, collagen and 
cathepsin)
Increase73,74 Increase71
Airway hyper‐responsiveness Increase77,78 Increase79
Total leucocytes in BALF Increase77 
No78
Increase79
Percentage/number of eosinophils in BALF Increase77,78 Increase79
IgE in serum Increase77,78 Increase79
Th2 cytokine production (ie IL‐4, IL‐5) in BALF Increase78 Increase79
IL‐13 production in BALF No77 
Increase78
Increase79
IFN‐γ production in BALF Increase80 Decrease79
Food/energy uptake Decrease67 Decrease81
Blood glucose N/A Increase81
Hepatic glycogen rate N/A Decrease81
Total cholesterol N/A Decrease81
LDL release N/A Decrease81
Hepatotoxicity N/A Increase81
BALF: bronchoalveolar lavage fluid; CS: cigarette smoke; E‐cigarette: electronic cigarette; IL: interleukin; 
IFN‐γ: interferon‐γ; LDL: low‐density lipoprotein.
T A B L E  4  The effects of CS and 
E‐cigarette on murine models in vivo
   | 9CHEN Et al.
that acute exposure to e‐cigarette aerosol in mouse lung in-
duces inflammatory responses. Chronic exposure of mice to 
nicotine‐containing ECV over a 4‐month period induced re-
spiratory resistance and alveolar airspace enlargement remi-
niscent of features of COPD,71 as also found in CS‐exposed 
mice.72-74 Moreover, the nicotine‐containing ECV induced 
increased levels of IL‐1β and MCP‐1 in the lungs, as well as 
protease, collagenase and cathepsin expression, all of which 
are involved in the pathogenesis of COPD. These changes 
were not induced by ECVs lacking nicotine, thus supporting 
the direct harmful effects of nicotine. All these inflammatory 
mediators and enzymes were similarly found to be stimulated 
in other experiments treating mice with CS.72-76
In addition to inducing COPD‐like symptoms, another 
murine study demonstrated that both CS and E‐cigarette 
fluid can exacerbate the signs and symptoms of experi-
mental asthma induced by sensitization of mice to oval-
bumin. Airway hyper‐responsiveness was significantly 
increased by CS in OVA‐sensitized mice77,78 and also 
by intra‐tracheal instillation of E‐liquid twice a week for 
10 weeks.79 Furthermore, the total number of leucocytes 
in BALF was higher in OVA‐sensitized mice also exposed 
to CS77 or E‐liquid,79 as was the percentage/number of eo-
sinophils.77-80 CS elevated OVA‐specific IgE in serum77,78 
and increased OVA‐induced Th2 cytokines IL‐4 and IL‐5 
in BALF,78 whereas the production of IL‐13 varied.77,78 
Levels of OVA‐specific IgE in serum, and IL‐4, IL‐5 and 
IL‐13 in BALF, were all higher in OVA‐sensitized mice 
with E‐liquid than those without, whereas interferon 
(IFN)‐γ was lower which was contradictory to one study 
using CS.80 Th2 cytokines are the crucial players in the 
pathogenesis of atopic asthma, and IFN‐γ counteracts the 
Th2 immune responses; thus, a reduction in IFN‐γ levels 
caused by E‐liquid exposure might exacerbate Th2‐domi-
nated inflammatory responses. In conclusion, these results 
indicate that E‐liquid exposure aggravated allergen‐in-
duced asthmatic inflammation and use of E‐cigarettes in 
asthmatic people might exacerbate their symptoms.
In addition to respiratory effects, mice exposed to CS67 
or injected with nicotine and nicotine‐containing E‐liquid 
for 4 weeks81 had significantly less food and energy intake. 
Furthermore, nicotine or E‐liquid (with or without nicotine) 
elevated blood glucose levels but inhibited hepatic glycogen 
rate. Also, nicotine or E‐liquid (with or without nicotine) 
might help lipid profile by decreasing total cholesterol and 
low‐density lipoprotein (LDL) but increase hepatotoxicity. 
Therefore, E‐liquid might induce metabolic disorder by dis-
turbing both glucose and cholesterol homeostasis, indepen-
dent of nicotine. It should be borne in mind, however, that 
direct application of E‐liquids themselves (as in the above 
studies) may not be equivalent to ECV in the effects exerted. 
The relevance of these findings to ECV inhalation may there-
fore be questioned.
2.6 | Effects of E‐cigarettes on resistance 
to infection
Platelet‐activating factor receptor (PAFR) is used by pneumo-
cocci to adhere to host cells, and CS increases pneumococcal 
adhesion by up‐regulating PAFR expression in human lower 
epithelial cells (Table 5).82 The increased levels of nasal PAFR 
were seen in adults inhaling E‐cigarette vapour for 5 min-
utes.83 ECVE (with or without nicotine) also increase pneu-
mococcal adhesion to a human epithelial cell line, and this 
was related to ROS production. Since pneumococcal infection 
is the commonest cause of bacterial pneumonia, E‐cigarette 
use has the potential to facilitate pneumococcal diseases.
Electronic cigarette vapour may impair defence against 
bacterial and viral infections, resulting in increasing patho-
gen burden and pro‐inflammatory cytokine production whilst 
suppressing phagocytic and defensive abilities of cells. For 
example, treatment of normal human tracheobronchial epi-
thelial cells with tobacco‐flavoured E‐liquid, with or with-
out nicotine, increased the virus load after human rhinovirus 
(HRV) infection and augmented HRV‐induced IL‐6 produc-
tion. Moreover, SPLUNC1, a host defence molecule against 
HRV infection, was suppressed by E‐liquids with and without 
nicotine.84
Cigarette smoke caused higher pulmonary bacterial 
burden of methicillin‐resistant Staphylococcus aureus in 
mice, which was due to augmented evasion of phagocy-
tosis and neutrophil extracellular trap‐mediated killing.85 
With regard to immunity to bacteria, exposure to ECV 
prior to bacterial infection led to greater numbers of meth-
icillin‐resistant S. aureus in epithelial cells, alveolar mac-
rophages and human polymorphonuclear leucocytes, which 
are responsible for clearance of inhaled pathogens and host 
defence of the lung against bacteria. This reduction in anti‐
bacterial activity was seen upon treatment with nicotine or 
humectants, as well as complete ECV. Increased virulence 
of the bacteria themselves was also induced by exposing 
them to ECV extract.70
Bacterial burden was significantly increased in the lungs 
of both CS‐86 and ECV‐exposed87 mice after Streptococcus 
T A B L E  5  The effects of CS and E‐cigarette on resistance to 
infection
Effect CS E‐cigarette
PAFR level Increase82 Increase83
Pathogen adhesion Increase82 Increase83
Pathogen burden Increase85,86 Increase70,84,87
IL‐6 production N/A Increase84
Host defence molecule 
SPLUNC1
N/A Decrease84
IL‐17A production N/A Decrease87
CS: cigarette smoke; E‐cigarette: electronic cigarette; IL: interleukin.
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pneumoniae infection, and this was associated with reduced 
bacterial clearance by alveolar macrophages. ECV exposure 
also caused greater severity of influenza infection in mice, 
with higher viral titres and increased mortality, but reduced 
levels of IL‐17A which is associated with protective immu-
nity against influenza infection.87
2.7 | The effects of E‐liquid constituents 
other than nicotine
The studies described above show the potentially deleteri-
ous effects of E‐cigarettes (Table 6). These effects are not 
entirely attributable to nicotine, indicating that other com-
ponents in E‐liquids may also be damaging. In addition to 
nicotine, humectants (ie, propylene glycol and vegetable 
glycerol) and flavourings are the major ingredients of E‐
liquids. Humectants are the bases, or carriers, for nicotine 
and flavourings, and most E‐liquids contain both propylene 
glycol (PG) and vegetable glycerol (VG) at a ratio of 50/50 
or 70/30. PG is widely used in food and inhaled therapeutic 
products and can deliver a strong throat hit which may cause 
a slight irritation after use. VG, which has a slightly sweet 
taste, can soften the feeling in the throat and generate thicker 
and more visible vapours. The levels of oxidants and/or ROS 
detected in aerosols of PG and VG were significantly higher 
than in air alone.40 Both PG and VG also induced death of 
normal HBECs, and the effects of glycerol were more potent 
than complete E‐liquid.33 Moreover, cells exposed to PG or 
VG showed higher levels of oxidative stress than when ex-
posed to air.33 PG/VG mixture also had negative effects on 
cell viability of embryonic kidney 293 cells, human adeno-
carcinoma alveolar basal epithelial cells and human airway 
smooth muscle cells, in a dose‐dependent manner.88
More than seven thousand flavourings for E‐cigarettes are 
now available, with over 70% of E‐liquids containing greater 
than 1% flavoured chemical levels by weight.89 Although 
most of the flavourings are defined as safe to be used in 
food products, the potential toxicity associated with degra-
dation products generated by vaping at high temperatures is 
unknown. Significantly elevated ROS production was dis-
covered in classic tobacco‐flavoured (16 mg of nicotine) and 
menthol‐flavoured (0 mg of nicotine) ECVs.40 However, clas-
sic tobacco‐flavoured ECVs gave relatively reduced ROS pro-
duction when nicotine was also present. Similarly, E‐liquids 
with either high or low concentration of nicotine had signifi-
cantly less ROS than those without nicotine, suggesting nic-
otine is not a crucial inducer of ROS production. Moreover, 
E‐liquids with non‐tobacco flavouring had higher ROS than 
tobacco flavoured E‐liquid, indicating that the occurrence of 
ROS in E‐liquids is associated with the type of flavourings. 
The levels of ROS present in fruit‐flavoured ECVs can up to 
threefold higher than in tobacco‐flavoured ECV.90
Flavouring also has an impact on inflammatory re-
sponses: For example, nicotine‐free cinnamon roll‐fla-
voured ECV induced high IL‐8 secretion from human lung 
fibroblasts.40 2,5‐Dimethylpyrazine, an odorant compound 
in dark chocolate, reduced the capacity of airway epithelial 
cells to respond to cyclic adenosine monophosphate and ex-
ogenous ATP which are crucial factors for normal airway 
epithelial cell functions, like mucociliary clearance.91 2,5‐
Dimethylpyrazine also increased ion conductance by evoking 
protein kinase A‐dependent (PKA) activation of the cystic 
fibrosis transmembrane conductance regulator ion channel. 
Menthol, coffee and strawberry‐flavoured ECVs reduced 
both cell viability and metabolic activity, while coffee and 
strawberry‐flavoured ECVS also induced cytokine produc-
tion in human bronchial cells.92 CALU3 airway epithelial cell 
line proliferation was inhibited by all 13 flavoured E‐liquids 
T A B L E  6  The effects of E‐liquid constituents other than nicotine
Effect
Other constituents and 
flavourings
Increase oxidative stress Humectants,33,40 classic tobacco,40 
menthol40
Alteration in cytokine 
production
Cinnamon roll,40 coffee,92 
strawberry,92 sini‐cide,94 kola,94 
cinnamaldehyde95
Reduce cAMP response 2,5‐Dimethylpyrazine91
Reduce exogenous ATP 
response
2,5‐Dimethylpyrazine91
Increase PKA activation 2,5‐Dimethylpyrazine91
Reduce cell viability Humectants,33,88 menthol,92 
strawberry,92 coffee,92 Peanut 
butter cookie,93 banana pudding,93 
kola,93 hot cinnamon candies93
Reduce metabolic activity Menthol,92 strawberry,92 coffee92
Reduced cell number Peanut butter cookie,93 banana 
pudding,93 kola,93 hot cinnamon 
candies93
Reduce cell proliferation Captain black cigar,93 Peanut butter 
cookie,93 T‐bone,93 popcorn, black 
licorice,93 energon,93 vanilla 
tobacco,93 banana pudding,93 
kola,93 hot cinnamon candies,93 
menthol tobacco,93 solid menthol93
Increase LDH release Kola,93 hot cinnamon candies,93 
menthol tobacco93
Decrease phagocytosis of 
alveolar macrophages
sini‐cide,94 kola94
Decrease phagocytosis of 
airway neutrophils
Hot cinnamon candies,94 banana 
pudding,94 menthol tobacco,94 
banana, sini‐cide94
Alteration in NET 
formation
sini‐cide,94 kola94
cAMP: cyclic adenosine monophosphate; E‐liquid: E‐cigarette liquid; NET: 
neutrophil extracellular traps.
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tested in a dose‐dependent manner.93 Peanut butter cookies, 
banana pudding, kola, hot cinnamon candies and menthol 
tobacco caused significantly reduced cell numbers and vi-
ability compared with the PG/VG mixture. Moreover, kola, 
hot cinnamon candies and menthol tobacco increased pro-
duction of the cytotoxic marker LDH. Aerosolized E‐liquids 
had similar toxicity profiles to neat E‐liquids. Sini‐cide and 
kola‐flavoured E‐liquid altered phagocytic ability and cyto-
kine production in alveolar macrophages.94 Moreover, hot 
cinnamon candies, banana pudding, menthol tobacco and 
sini‐cide affected phagocytosis of human airway neutrophils 
in comparison with PG/VG mixture. Kola and sini‐cide also 
altered formation of neutrophil extracellular traps (NETs), 
which contain chromatin filaments and granule protein to 
expel extracellular pathogens, and killing reduced the effi-
ciency of NK cells. These three flavourings all contained 
cinnamaldehyde, which, on its own, showed similar effects, 
suggesting the potentials of cinnamaldehyde for impairing 
respiratory immune cell function. Another study also pointed 
out the deleterious effects of cinnamaldehyde: both flavour-
ing chemicals and flavoured E‐liquid without nicotine‐re-
duced cell viability and IL‐8 secretion of monocytic cell 
lines dose‐dependently, with cinnamaldehyde showing the 
highest cytotoxicity.95 Flavouring chemicals and seven types 
of aerosolized E‐liquids including American tobacco, café 
latte and cinnamon roll induced cell‐free ROS production.95 
Interestingly, mixing a variety of flavours induced higher cy-
totoxicity and cell‐free ROS levels compared to individual 
flavours. This might give a warning of greater toxic effects to 
those users who mix E‐liquids or those who are exposed to 
multiple flavourings in public areas.
A comprehensive study examined the effects of 35 fla-
vours of E‐liquid on human embryonic stem cells (hESC), 
mouse neural stem cells (mNSC) and human pulmonary fi-
broblasts (hPF).96 Cinnamon Ceylon flavour was the most cy-
totoxic to all three cell types, whilst butterscotch was defined 
as having relatively low cytotoxicity. However, the possibil-
ity of harm being caused by the latter cannot be excluded, 
since some workers at microwave popcorn packaging plants 
developed the irreversible obstructive lung disease, bron-
chiolitis obliterans, due to exposure to the butter flavouring 
component diacetyl.97 Three E‐liquids all named butterscotch 
flavour induced different levels of cytotoxicity, although 
they were from the same company. hESC and mNSC were 
more sensitive to E‐liquids than hPF (except for caramel and 
Menthol Arctic, which had stronger effects on hPF), suggest-
ing that cells from embryos and newborns are generally more 
sensitive to E‐cigarette constituents. There was no correlation 
between cytotoxicity and nicotine levels, as the cells did not 
survive better in E‐liquids without nicotine.
In addition to humectants and flavourings, other chemi-
cals and metals (eg, copper, nickel and titanium) are detected 
in E‐liquids. Copper metal nanoparticles could stimulate the 
production of mitochondrial ROS and reduction of mito-
chondrial membrane potential in human lung fibroblasts.40 A 
quarter of E‐liquids contain aldehyde (eg, benzaldehyde and 
vanillin)89 and significant amounts of formaldehyde, acetal-
dehyde and propionaldehyde were found in E‐liquid heated at 
150°C.98 Aldehydes are recognized as primary irritants of the 
mucosa of the respiratory tract and acetaldehyde exposure 
impairs mucus clearance, leading to decreased host defence. 
Benzaldehyde, which can cause irritation of the respiratory 
airways and eyes, is a major ingredient in fruit‐flavourings. 
Cherry‐flavoured E‐liquid was found to contain the greatest 
concentration of benzaldehyde, and the benzaldehyde doses 
inhaled with 30 puffs from E‐cigarettes were often higher 
than doses inhaled from conventional cigarettes.99 Tobacco‐
specific nitrosamines (TSNAs) are known carcinogenic 
compounds in conventional cigarettes, especially NNK and 
NNN, which exert the strongest carcinogenicity. TSNAs were 
also detected in both liquid100 and vapour10 of E‐cigarettes. 
However, conventional cigarettes contain up to 1800 times 
higher amounts of NNK and NNN than E‐cigarettes.101
3 |  DISCUSSION
Electronic cigarettes are battery‐operated devices that gener-
ate vapours by heating liquid mainly containing humectants, 
nicotine and flavourings. E‐cigarettes have seen a rapid rise 
in use since the introduction to the market because of the 
perception that they are safer than conventional cigarettes, 
and their appealing design; however, there are many unan-
swered questions regarding their health impacts on humans. 
There is accumulating evidence demonstrating the effects of 
E‐cigarettes on both human and murine models, and com-
parison between E‐cigarette and conventional cigarettes has 
also been made. With respect to the latter, numerous studies 
have indicated that ECV can induce similar effects to CS, but 
to a lesser extent. This may mean that smoking E‐cigarettes 
is unlikely to be as deleterious to health as smoking conven-
tional cigarettes; however, the relatively recent widespread 
introduction of E‐cigarettes means that it is too early to know 
the potential consequences, for an individual, of using E‐cig-
arettes for several decades. A very important aspect of this is 
the carcinogenic potential of E‐cigarettes compared to con-
ventional cigarettes. Once again, however, it is too early to 
draw conclusions about the actual carcinogenicity of ECVs.
Gingival epithelial cells, the most abundant structural 
cells in gingiva, are in direct contact with vapours from 
smoking devices. As described in previous section, both CS 
and ECV induced death of gingival epithelial cells, associ-
ated with the elevation of caspase‐3 activity, which is a fre-
quently activated protease in cell apoptosis. Moreover, ECV 
altered the morphology of the cells, resulting in large faint 
nuclei, enlarged cytoplasm and compromised integrity of 
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the plasma membrane. Gingival fibroblasts are important in 
wound healing through their adhesion, proliferation and mi-
gration, which were affected negatively by both CS and ECV. 
As CS is a well‐established risk factor for periodontitis, these 
findings indicate that ECV might also provide an unhealthy 
oral environment and promote periodontal disease. Indeed, 
two clinical cases were reported of patients with more than 
a 10‐year history of E‐cigarette use, but no other identifi-
able risk factors, developed basaloid squamous cell oral car-
cinoma, suggesting a potential role for ECV in oral cancer 
development.102
A clinical case report described a previously healthy in-
dividual who started coughing, with whitish secretions, and 
who developed progressive dyspnoea after E‐cigarette use 
for 48 hours; wheezing was revealed by auscultation after 
4 weeks. However, these symptoms improved gradually and 
were abolished without any treatment a week after cessation 
of E‐cigarette use.103 Another case report described a pre-
sentation of hypersensitivity pneumonitis associated with 
E‐cigarette use.104 Also, a 46‐year‐old healthy man devel-
oped respiratory distress, night sweats, fever and weight loss 
after using E‐cigarette for a month. He was found to have 
BALF that contained abundant lipid‐laden macrophages, 
eosinophils and neutrophils. The symptoms were fully abol-
ished after E‐cigarette abstinence.105 These clinical cases 
illustrate that E‐cigarettes can have a negative impact on 
respiratory health. Respiratory epithelium is a ciliated epi-
thelium forming the integral barrier against inhaled agents 
to prevent infection and injury by trapping and expelling 
particles (mucociliary clearance), phagocytosing and killing 
pathogens and recruiting immune cells. It is known that CS 
alters respiratory epithelium by compromising its integrity 
and impairing mucociliary clearance. According to the find-
ings described in a previous section about respiratory system, 
ECV also induced morphological changes, cell death, LDH 
release and inflammatory mediator production by bronchial 
epithelial cells. Furthermore, ECV might compromise muco-
ciliary clearance by down‐regulating the expression of genes 
related to assembly and movement of cilia. Although some 
studies observed a lower magnitude of effects than those 
caused by CS, ECV is also able to damage respiratory epithe-
lium and evoke an inflammatory environment. Using human 
models, both direct exposure and passive ECV exposure were 
found to facilitate adverse respiratory effects including alter-
ations in transcriptome/protein expression related to various 
biological functions, increased bronchitic symptoms, airway 
flow resistance and oxidative stress measured by FeNO.
Oxidative stress, which reflects an imbalance between 
oxidants and antioxidants, is critical in injurious and inflam-
matory responses in respiratory diseases.106 Oxidative stress 
causes damage to airway epithelium by increasing epithe-
lial cell lysis and detachment after CS exposure, and trig-
gers the release of inflammatory mediators such as IL‐1 and 
IL‐8 which are involved in activation of the NF‐κB pathway. 
Tobacco smokers have higher levels of oxidative stress in the 
lungs, which arises not only from oxidants in cigarettes, but 
also ROS from macrophages and neutrophils via the NADPH 
system. Excessive ROS damage cells and tissue, leading to 
induction of cell death.107 These mechanisms might also ex-
plain oxidative stress‐induced deleterious effects of E‐ciga-
rettes since ECV causes high levels of oxidative stress in a 
variety of cell types, as discussed in previous sections.
Alveolar macrophages are crucial in innate immune re-
sponses in lungs. As mentioned in previous sections, both 
CS and ECV induced the production of pro‐inflammatory 
mediators and proteolytic enzymes which damage connec-
tive tissues and parenchymal cells of lungs, thereby provid-
ing cellular mechanisms that connect smoking/vaping and 
inflammation and tissue damage. Moreover, increased ROS 
production can help the killing of intracellular pathogens; 
however, phagocytosis of alveolar macrophages was com-
promised by both CS and ECV, suggesting their roles in im-
pairing defence ability. Excessive inflammatory mediators 
and functional impairment of alveolar macrophages could 
contribute to lung pathogenesis including chronic bronchitis 
and emphysema. In previous sections, both CS and ECV re-
duced the production of inflammatory mediators associated 
with an anti‐viral response by bronchial epithelial cells, show-
ing that both CS and ECV might increase susceptibility to 
infection, which is the main factor in the acute exacerbation 
of COPD. It was reported in animal models that chronic expo-
sure to CS suppressed bacterial clearance from the lungs and 
induced COPD‐like damage in the lungs. ECV also impaired 
resistance to infection in mice, leading to higher burden and 
adhesion of pathogens, which might be due to inhibition of 
defence mechanism (ie lower levels of SPLUNC1, IL‐17 and 
clearance activity by leucocytes).
Cigarette smoke has been documented to have a neg-
ative impact on many aspects of human health and to be 
a risk factor for various diseases. In particular, tobacco 
smoking is a risk factor for a range of cancers, respiratory 
diseases and infections, cardiovascular diseases and delete-
rious effects on the immune system.108,109 ECV also exerts 
systemic effects on various cells and tissues. Neutrophils 
are recruited to the lung and stimulate enzymes that break 
down collagen, elastin and extracellular matrix and mucus 
production after CS exposure, leading to the development 
of emphysema and chronic bronchitis, major characteris-
tics of COPD. In addition, smokers who developed COPD 
have higher numbers of circulating neutrophils.110 We have 
described in previous sections that sputum of E‐cigarette 
users has a raised neutrophil count, neutrophilic enzyme 
production and NET formation, which promote antimicro-
bial ability. Moreover, ECV could activate neutrophils and 
inflammatory mediator production in vitro. ECV might 
be harmful to the cardiovascular system as it was found to 
   | 13CHEN Et al.
reduce endothelial functions, decrease cell viability and in-
duce oxidative stress and complement deposition: All these 
factors could promote the development of cardiovascular 
disease. Habitual E‐cigarette users showed sympathetic 
predominance and higher oxidative stress levels. Viability 
and density of Kupffer cells were decreased by ECV while 
complement deposition, oxidative stress and inflammatory 
mediators were induced, suggesting that ECV might trigger 
inflammation in the liver. In murine models, ECV was able 
to affect not only respiratory system, but also body growth, 
energy intake and metabolism.
A clinical case report described an E‐cigarette user 
who developed respiratory symptoms that coincided with 
her onset of E‐cigarette use and was given a diagnosis 
of lipid pneumonia.111 Lipid pneumonia results from ac-
cumulation of either exogenous or endogenous lipids in 
the alveoli. Glycerine is obtained from plants by heating 
palm or coconut oils or soap via a fatty acid splitting op-
eration; therefore, glycerine‐based oil in E‐cigarettes was 
suspected to be the exogenous source of lipids that induced 
lipid pneumonia in this individual. Flavourings have in-
creased the appeal of E‐cigarettes to adolescents and pre-
vious intermittent smokers; the FDA planned to limit sale 
of flavoured E‐cigarette to crackdown the “epidemic” use 
of E‐cigarettes amongst the young.16 Indeed, as discussed 
in previous sections, many flavoured E‐cigarettes had ad-
verse effects in vitro, and there are many more E‐ciga-
rette flavourings on the market waiting to be investigated. 
Although humectants, nicotine and flavourings are labelled 
as the ingredients in most commercial E‐liquids, metals 
and other chemicals such as carbonyls and tobacco‐specific 
nitrosamines, which are toxic and carcinogenic, have been 
detected in E‐liquids.
There are limitations studying the effects of E‐cigarettes, 
such as types of E‐cigarette devices and E‐liquid used and 
patterns of E‐cigarette exposure (ie duration and frequency). 
Quantifying E‐cigarette exposure is more challenging than 
conventional cigarette exposure, which can be calculated by 
the number of cigarettes smoked per day. In those human 
studies, it is also difficult to certain that the participants did 
not use conventional cigarette surreptitiously or have been 
exposed to CS‐containing environment.
4 |  CONCLUSION
Electronic cigarette vapours induce many alterations in a 
variety of cell types, including suppression of cell viabil-
ity, morphological changes, production of pro‐inflamma-
tory cytokines and inhibition of defence against bacteria 
and viruses. In addition to in vitro models, murine and 
human in vivo studies also demonstrate potentially delete-
rious effects of E‐cigarettes, indicating they may not be as 
safe as initially assumed and have effects like those of CS, 
although possibly less severe; a caveat to this is that it is 
still too early to know what effects E‐cigarettes may have 
in an individual over several decades of use. The effects of 
E‐cigarettes are attributable not only to nicotine but also to 
humectants, different flavourings and other constituents. In 
conclusion, we cannot neglect the potential negative health 
impact of E‐cigarettes and the need for public awareness 
of this.
CONFLICTS OF INTEREST
The authors have no conflicts of interest to declare.
REFERENCES
 1. Herzog B, Gerberi J. E‐cigs Revolutionizing the Tobacco Industry. 
Clearwater, FL: Wells Fargo Securities; 2013:1‐15.
 2. King BA, Alam S, Promoff G, Arrazola R, Dube SR. Awareness 
and ever‐use of electronic cigarettes among U.S. adults, 2010–
2011. Nicotine Tob Res. 2013;15(9):1623‐1627.
 3. Eastwood B, Dockrell MJ, Arnott D, et al. Electronic cigarette 
use in young people in Great Britain 2013–2014. Public Health. 
2015;129(9):1150‐1156.
 4. Lam DC, Nana A, Eastwood PR, Asian‐Pacific Society of R. 
Electronic cigarettes: 'vaping' has unproven benefits and potential 
harm. Respirology. 2014;19(7):945‐947.
 5. Goniewicz ML, Lingas EO, Hajek P. Patterns of electronic ciga-
rette use and user beliefs about their safety and benefits: an inter-
net survey. Drug Alcohol Rev. 2013;32(2):133‐140.
 6. Polosa R, Morjaria JB, Caponnetto P, et al. Effectiveness and 
tolerability of electronic cigarette in real‐life: a 24‐month pro-
spective observational study. Intern Emerg Med. 2014;9(5): 
537‐546.
 7. Beard E, West R, Michie S, Brown J. Association between elec-
tronic cigarette use and changes in quit attempts, success of quit 
attempts, use of smoking cessation pharmacotherapy, and use of 
stop smoking services in England: time series analysis of popula-
tion trends. BMJ. 2016;354:i4645.
 8. Etter JF. Electronic cigarettes: a survey of users. BMC Public 
Health. 2010;10:231.
 9. Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D, 
Russo C. Effect of an electronic nicotine delivery device (e‐
Cigarette) on smoking reduction and cessation: a prospective 6‐
month pilot study. BMC Public Health. 2011;11:786.
 10. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected 
carcinogens and toxicants in vapour from electronic cigarettes. 
Tob Control. 2014;23(2):133‐139.
 11. Dawkins L, Turner J, Roberts A, Soar K. 'Vaping' profiles and 
preferences: an online survey of electronic cigarette users. 
Addiction. 2013;108(6):1115‐1125.
 12. Coleman BN, Johnson SE, Tessman GK, et al. "It's not smoke. It's 
not tar. It's not 4000 chemicals. Case closed": exploring attitudes, 
beliefs, and perceived social norms of e‐cigarette use among adult 
users. Drug Alcohol Depend. 2016;159:80‐85.
 13. WHO. Countries vindicate cautious stance on e‐cigarettes. 2014. 
https://www.who.int/bulletin/volumes/92/12/14-031214/en/. 
Accessed December 12, 2014.
14 |   CHEN Et al.
 14. WHO. Tobacco free initiative. 2013.
 15. Kennedy RD, Awopegba A, De León E, Cohen JE. Global ap-
proaches to regulating electronic cigarettes. Tobacco Control. 
2017;26(4):440‐445.
 16. (FDA) UFaDA. Statement from FDA Commissioner Scott Gottlieb, 
M.D., on proposed new steps to protect youth by preventing access to 
flavored tobacco products and banning menthol in cigarettes. 2018. 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm625884.htm. Accessed November 15, 2018.
 17. Goniewicz ML, Gawron M, Smith DM, Peng M, Jacob P 3rd, 
Benowitz NL. Exposure to nicotine and selected toxicants in 
cigarette smokers who switched to electronic cigarettes: a lon-
gitudinal within‐subjects observational study. Nicotine Tob Res. 
2017;19(2):160‐167.
 18. Cibella F, Campagna D, Caponnetto P, et al. Lung function and 
respiratory symptoms in a randomized smoking cessation trial of 
electronic cigarettes. Clin Sci (Lond). 2016;130(21):1929‐1937.
 19. Campagna D, Cibella F, Caponnetto P, et al. Changes in breath-
omics from a 1‐year randomized smoking cessation trial of elec-
tronic cigarettes. Eur J Clin Invest. 2016;46(8):698‐706.
 20. Polosa R, Cibella F, Caponnetto P, et al. Health impact of E‐cig-
arettes: a prospective 3.5‐year study of regular daily users who 
have never smoked. Sci Rep. 2017;7(1):13825.
 21. Polosa R, Morjaria JB, Caponnetto P, et al. Evidence for harm 
reduction in COPD smokers who switch to electronic cigarettes. 
Respir Res. 2016;17(1):166.
 22. Polosa R, Morjaria JB, Caponnetto P, et al. Persisting long term 
benefits of smoking abstinence and reduction in asthmatic smok-
ers who have switched to electronic cigarettes. Discov Med. 
2016;21(114):99‐108.
 23. Polosa R, Morjaria JB, Caponnetto P, et al. Blood pressure control 
in smokers with arterial hypertension who switched to electronic 
cigarettes. Int J Environ Res Public Health. 2016;13(11):1123. 
https://doi.org/10.3390/ijerph13111123
 24. Poggi P, Rota MT, Boratto R. The volatile fraction of cigarette 
smoke induces alterations in the human gingival fibroblast cyto-
skeleton. J Periodontal Res. 2002;37(3):230‐235.
 25. Zhang W, Fang M, Song F, Windsor LJ. Effects of cigarette smoke 
condensate and nicotine on human gingival fibroblast‐mediated 
collagen degradation. J Periodontol. 2011;82(7):1071‐1079.
 26. Semlali A, Chakir J, Rouabhia M. Effects of whole cigarette 
smoke on human gingival fibroblast adhesion, growth, and migra-
tion. J Toxicol Environ Health A. 2011;74(13):848‐862.
 27. Sancilio S, Gallorini M, Cataldi A, di Giacomo V. Cytotoxicity 
and apoptosis induction by e‐cigarette fluids in human gingival 
fibroblasts. Clin Oral Investig. 2016;20(3):477‐483.
 28. Alanazi H, Park HJ, Chakir J, Semlali A, Rouabhia M. 
Comparative study of the effects of cigarette smoke and electronic 
cigarettes on human gingival fibroblast proliferation, migration 
and apoptosis. Food Chem Toxicol. 2018;118:390‐398.
 29. Kim M‐S, Yun J‐W, Park J‐H, et al. Autophagy has a benefi-
cial role in relieving cigarette smoke‐induced apoptotic death in 
human gingival fibroblasts. Int J Med Sci. 2016;13(5):357.
 30. Alamri A, Semlali A, Jacques É, et al. Long‐term exposure of 
human gingival fibroblasts to cigarette smoke condensate reduces 
cell growth by modulating Bax, caspase‐3 and p 53 expression. J 
Periodontal Res. 2015;50(4):423‐433.
 31. Semlali A, Chakir J, Goulet JP, Chmielewski W, Rouabhia M. 
Whole cigarette smoke promotes human gingival epithelial cell 
apoptosis and inhibits cell repair processes. J Periodontal Res. 
2011;46(5):533‐541.
 32. Rouabhia M, Park HJ, Semlali A, Zakrzewski A, Chmielewski 
W, Chakir J. E‐cigarette vapor induces an apoptotic response in 
human gingival epithelial cells through the caspase‐3 pathway. J 
Cell Physiol. 2017;232(6):1539‐1547.
 33. Scheffler S, Dieken H, Krischenowski O, Forster C, Branscheid 
D, Aufderheide M. Evaluation of E‐cigarette liquid vapor and 
mainstream cigarette smoke after direct exposure of primary 
human bronchial epithelial cells. Int J Environ Res Public Health. 
2015;12(4):3915‐3925.
 34. Taylor M, Carr T, Oke O, et al. E‐cigarette aerosols induce lower 
oxidative stress in vitro when compared to tobacco smoke. Toxicol 
Mech Methods. 2016;26(6):465‐476.
 35. Moses E, Wang T, Corbett S, et al. Molecular impact of electronic 
cigarette aerosol exposure in human bronchial epithelium. Toxicol 
Sci. 2017;155(1):248‐257.
 36. Cervellati F, Muresan XM, Sticozzi C, et al. Comparative effects 
between electronic and cigarette smoke in human keratinocytes 
and epithelial lung cells. Toxicol In Vitro. 2014;28(5):999‐1005.
 37. Anthérieu S, Garat A, Beauval N, et al. Comparison of cellular 
and transcriptomic effects between electronic cigarette vapor and 
cigarette smoke in human bronchial epithelial cells. Toxicol In 
Vitro. 2017;45:417‐425.
 38. Higham A, Bostock D, Booth G, Dungwa JV, Singh D. The ef-
fect of electronic cigarette and tobacco smoke exposure on COPD 
bronchial epithelial cell inflammatory responses. Int J Chron 
Obstruct Pulmon Dis. 2018;13:989‐1000.
 39. Przybyla RJ, Wright J, Parthiban R, Nazemidashtarjandi S, Kaya 
S, Farnoud AM. Electronic cigarette vapor alters the lateral struc-
ture but not tensiometric properties of calf lung surfactant. Respir 
Res. 2017;18(1):193.
 40. Lerner CA, Sundar IK, Yao H, et al. Vapors produced by elec-
tronic cigarettes and e‐juices with flavorings induce toxicity, ox-
idative stress, and inflammatory response in lung epithelial cells 
and in mouse lung. PLoS One. 2015;10(2):e0116732.
 41. Lerner CA, Rutagarama P, Ahmad T, Sundar IK, Elder A, Rahman 
I. Electronic cigarette aerosols and copper nanoparticles induce 
mitochondrial stress and promote DNA fragmentation in lung fi-
broblasts. Biochem Biophys Res Commun. 2016;477(4):620‐625.
 42. Ahmad T, Sundar IK, Lerner CA, et al. Impaired mitophagy 
leads to cigarette smoke stress‐induced cellular senescence: im-
plications for chronic obstructive pulmonary disease. FASEB J. 
2015;29(7):2912‐2929.
 43. Scott A, Lugg ST, Aldridge K, et al. Pro‐inflammatory effects 
of e‐cigarette vapour condensate on human alveolar macrophages. 
Thorax. 2018;73(12):1161‐1169.
 44. Aoshiba K, Tamaoki J, Nagai A. Acute cigarette smoke exposure 
induces apoptosis of alveolar macrophages. Am J Physiol Lung 
Cell Mol Physiol. 2001;281(6):L1392‐L1401.
 45. Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage‐
mediated elastolysis: roles of matrix metalloproteinases, cyste-
ine, and serine proteases. Am J Physiol Lung Cell Mol Physiol. 
2002;283(4):L867‐L873.
 46. Kotani N, Hashimoto H, Sessler DI, et al. Smoking decreases 
alveolar macrophage function during anesthesia and surgery. 
Anesthesiology. 2000;92(5):1268‐1277.
 47. Chen H, Cowan MJ, Hasday JD, Vogel SN, Medvedev AE. 
Tobacco smoking inhibits expression of proinflammatory 
   | 15CHEN Et al.
cytokines and activation of IL‐1R‐associated kinase, p38, and 
NF‐κB in alveolar macrophages stimulated with TLR2 and TLR4 
agonists. J Immunol. 2007;179(9):6097‐6106.
 48. Rahman I, Adcock I. Oxidative stress and redox regulation of lung 
inflammation in COPD. Eur Respir J. 2006;28(1):219‐242.
 49. Kougias M, Vardavas CI, Anagnostopoulos N, et al. The acute effect 
of cigarette smoking on the respiratory function and FENO produc-
tion among young smokers. Exp Lung Res. 2013;39(8):359‐364.
 50. Yoshida T, Tuder RM. Pathobiology of cigarette smoke‐in-
duced chronic obstructive pulmonary disease. Physiol Rev. 
2007;87(3):1047‐1082.
 51. Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou 
V, Connolly GN, Behrakis PK. Short‐term pulmonary ef-
fects of using an electronic cigarette: impact on respiratory 
flow resistance, impedance, and exhaled nitric oxide. Chest. 
2012;141(6):1400‐1406.
 52. McConnell R, Barrington‐Trimis JL, Wang K, et al. Electronic 
cigarette use and respiratory symptoms in adolescents. Am J 
Respir Crit Care Med. 2017;195(8):1043‐1049.
 53. Staudt MR, Salit J, Kaner RJ, Hollmann C, Crystal RG. Altered 
lung biology of healthy never smokers following acute inhalation 
of E‐cigarettes. Respir Res. 2018;19(1):78.
 54. Ghosh A, Coakley RC, Mascenik T, et al. Chronic E‐cigarette 
exposure alters the human bronchial epithelial proteome. Am J 
Respir Crit Care Med. 2018;198(1):67‐76.
 55. Tzortzi A, Teloniatis SI, Matiampa G, et al. Passive exposure 
to e‐cigarette emissions: immediate respiratory effects. Tob Prev 
Cessat. 2018;4:1‐8.
 56. Higham A, Rattray N, Dewhurst JA, et al. Electronic cigarette ex-
posure triggers neutrophil inflammatory responses. Respir Res. 
2016;17(1):56.
 57. Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil re-
sponse in chronic obstructive pulmonary disease. Thorax. 
2001;56(6):432‐437.
 58. Reidel B, Radicioni G, Clapp PW, et al. E‐cigarette use causes a 
unique innate immune response in the lung, involving increased 
neutrophilic activation and altered mucin secretion. Am J Respir 
Crit Care Med. 2018;197(4):492‐501.
 59. Moheimani RS, Bhetraratana M, Yin F, et al. Increased cardiac 
sympathetic activity and oxidative stress in habitual electronic 
cigarette users: implications for cardiovascular risk. JAMA 
Cardiol. 2017;2(3):278‐284.
 60. Antoniewicz L, Bosson JA, Kuhl J, et al. Electronic cigarettes in-
crease endothelial progenitor cells in the blood of healthy volun-
teers. Atherosclerosis. 2016;255:179‐185.
 61. Carnevale R, Sciarretta S, Violi F, et al. Acute impact of tobacco 
vs electronic cigarette smoking on oxidative stress and vascular 
function. Chest. 2016;150(3):606‐612.
 62. Barber KE, Ghebrehiwet B, Yin W, Rubenstein DA. Endothelial 
cell inflammatory reactions are altered in the presence of e‐cig-
arette extracts of variable nicotine. Cellular and Molecular 
Bioengineering. 2017;10(1):124‐133.
 63. Taylor M, Jaunky T, Hewitt K, et al. A comparative assessment 
of e‐cigarette aerosols and cigarette smoke on in vitro endothelial 
cell migration. Toxicol Lett. 2017;277:123‐128.
 64. Farsalinos K, Romagna G, Allifranchini E, et al. Comparison of 
the cytotoxic potential of cigarette smoke and electronic cigarette 
vapour extract on cultured myocardial cells. Int J Environ Res 
Public Health. 2013;10(10):5146‐5162.
 65. Rubenstein DA, Hom S, Ghebrehiwet B, Yin W. Tobacco and e‐
cigarette products initiate Kupffer cell inflammatory responses. 
Mol Immunol. 2015;67(2 Pt B):652‐660.
 66. McGrath‐Morrow SA, Hayashi M, Aherrera A, et al. The effects 
of electronic cigarette emissions on systemic cotinine levels, 
weight and postnatal lung growth in neonatal mice. PLoS One. 
2015;10(2):e0118344.
 67. Chen H, Vlahos R, Bozinovski S, Jones J, Anderson GP, 
Morris MJ. Effect of short‐term cigarette smoke exposure 
on body weight, appetite and brain neuropeptide Y in mice. 
Neuropsychopharmacology. 2005;30(4):713.
 68. Larcombe AN, Foong RE, Berry LJ, Zosky GR, Sly PD. In utero 
cigarette smoke exposure impairs somatic and lung growth in 
BALB/c mice. Eur Respir J. 2011;38:932‐938.
 69. Husari A, Shihadeh A, Talih S, Hashem Y, El Sabban M, Zaatari 
G. Acute exposure to electronic and combustible cigarette aero-
sols: effects in an animal model and in human alveolar cells. 
Nicotine Tob Res. 2016;18(5):613‐619.
 70. Hwang JH, Lyes M, Sladewski K, et al. Electronic cigarette in-
halation alters innate immunity and airway cytokines while in-
creasing the virulence of colonizing bacteria. J Mol Med (Berl). 
2016;94(6):667‐679.
 71. Garcia‐Arcos I, Geraghty P, Baumlin N, et al. Chronic electronic 
cigarette exposure in mice induces features of COPD in a nico-
tine‐dependent manner. Thorax. 2016;71(12):1119‐1129.
 72. Shu J, Li D, Ouyang H, et al. Comparison and evaluation of two 
different methods to establish the cigarette smoke exposure mouse 
model of COPD. Sci Rep. 2017;7(1):15454.
 73. Bracke KR, D'hulst AI, Maes T, et al. Cigarette smoke‐induced 
pulmonary inflammation and emphysema are attenuated in 
CCR73‐deficient mice. J Immunol. 2006;177(7):4350‐4359.
 74. Bracke KR, D'hulst AI, Maes T, et al. Cigarette smoke‐induced 
pulmonary inflammation, but not airway remodelling, is attenu-
ated in chemokine receptor 5‐deficient mice. Clin Exp Allergy. 
2007;37(10):1467‐1479.
 75. Pauwels NS, Bracke KR, Maes T, et al. Cigarette smoke induces 
PTX3 expression in pulmonary veins of mice in an IL‐1 depen-
dent manner. Respir Res. 2010;11(1):134.
 76. Castro P, Legora‐Machado A, Cardilo‐Reis L, et al. Inhibition of 
interleukin‐1β reduces mouse lung inflammation induced by expo-
sure to cigarette smoke. Eur J Pharmacol. 2004;498(1–3):279‐286.
 77. Moerloose KB, Pauwels RA, Joos GF. Short‐term cigarette smoke 
exposure enhances allergic airway inflammation in mice. Am J 
Respir Crit Care Med. 2005;172(2):168‐172.
 78. Kim DY, Kwon EY, Hong GU, Lee YS, Lee S‐H, Ro JY. Cigarette 
smoke exacerbates mouse allergic asthma through Smad proteins 
expressed in mast cells. Respir Res. 2011;12(1):49.
 79. Lim HB, Kim SH. Inhalation of e‐cigarette cartridge solution 
aggravates allergen‐induced airway inflammation and hyper‐re-
sponsiveness in mice. Toxicol Res. 2014;30(1):13‐18.
 80. Moerloose KB, Robays LJ, Maes T, Brusselle GG, Tournoy KG, 
Joos GF. Cigarette smoke exposure facilitates allergic sensitiza-
tion in mice. Respir Res. 2006;7(1):49.
 81. El Golli N, Dkhili H, Dallagi Y, et al. Comparison between elec-
tronic cigarette refill liquid and nicotine on metabolic parameters 
in rats. Life Sci. 2016;146:131‐138.
 82. Grigg J, Walters H, Sohal SS, et al. Cigarette smoke and plate-
let‐activating factor receptor dependent adhesion of Streptococcus 
pneumoniae to lower airway cells. Thorax. 2012;67(10):908‐913.
16 |   CHEN Et al.
 83. Miyashita L, Suri R, Dearing E, et al. E‐cigarette vapour enhances 
pneumococcal adherence to airway epithelial cells. Eur Respir J. 
2018;51(2). https://doi.org/10.1183/13993003.01592-2017
 84. Wu Q, Jiang D, Minor M, Chu HW. Electronic cigarette liquid 
increases inflammation and virus infection in primary human air-
way epithelial cells. PLoS One. 2014;9(9):e108342.
 85. Kulkarni R, Caskey J, Singh SK, et al. Cigarette smoke extract‐ex-
posed methicillin‐resistant Staphylococcus aureus regulates leu-
kocyte function for pulmonary persistence. Am J Respir Cell Mol 
Biol. 2016;55(4):586‐601.
 86. Phipps JC, Aronoff DM, Curtis JL, Goel D, O'Brien E, Mancuso P. 
Cigarette smoke exposure impairs pulmonary bacterial clearance 
and alveolar macrophage complement‐mediated phagocytosis of 
Streptococcus pneumoniae. Infect Immun. 2010;78(3):1214‐1220.
 87. Sussan TE, Gajghate S, Thimmulappa RK, et al. Exposure to elec-
tronic cigarettes impairs pulmonary anti‐bacterial and anti‐viral 
defenses in a mouse model. PLoS One. 2015;10(2):e0116861.
 88. Sassano MF, Davis ES, Keating JE, et al. Evaluation of e‐liquid 
toxicity using an open‐source high‐throughput screening assay. 
PLoS Biol. 2018;16(3):e2003904.
 89. Tierney PA, Karpinski CD, Brown JE, Luo W, Pankow JF. Flavour 
chemicals in electronic cigarette fluids. Tob Control. 2016;25(e1):
e10‐e15.
 90. Zhao J, Zhang Y, Sisler JD, et al. Assessment of reactive oxygen 
species generated by electronic cigarettes using acellular and cel-
lular approaches. J Hazard Mater. 2018;344:549‐557.
 91. Sherwood CL, Boitano S. Airway epithelial cell exposure to dis-
tinct e‐cigarette liquid flavorings reveals toxicity thresholds and 
activation of CFTR by the chocolate flavoring 2,5‐dimethypyra-
zine. Respir Res. 2016;17(1):57.
 92. Leigh NJ, Lawton RI, Hershberger PA,Goniewicz ML. 
Flavourings significantly affect inhalation toxicity of aerosol 
generated from electronic nicotine delivery systems (ENDS). Tob 
Control. 2016;25(Suppl 2):ii81‐ii87.
 93. Rowell TR, Reeber SL, Lee SL, et al. Flavored e‐cigarette 
liquids reduce proliferation and viability in the CALU3 air-
way epithelial cell line. Am J Physiol Lung Cell Mol Physiol. 
2017;313(1):L52‐L66.
 94. Clapp PW, Pawlak EA, Lackey JT, et al. Flavored e‐cigarette liq-
uids and cinnamaldehyde impair respiratory innate immune cell 
function. Am J Physiol Lung Cell Mol Physiol. 2017;313(2):L278
‐L292.
 95. Muthumalage T, Prinz M, Ansah KO, Gerloff J, Sundar IK, 
Rahman I. Inflammatory and oxidative responses induced by 
exposure to commonly used e‐cigarette flavoring chemicals and 
flavored e‐liquids without nicotine. Front Physiol. 2017;8:1130.
 96. Bahl V, Lin S, Xu N, Davis B, Wang YH, Talbot P. Comparison of 
electronic cigarette refill fluid cytotoxicity using embryonic and 
adult models. Reprod Toxicol. 2012;34(4):529‐537.
 97. Kreiss K, Gomaa A, Kullman G, Fedan K, Simoes EJ, Enright PL. 
Clinical bronchiolitis obliterans in workers at a microwave‐pop-
corn plant. N Engl J Med. 2002;347(5):330‐338.
 98. Hutzler C, Paschke M, Kruschinski S, Henkler F, Hahn J, Luch 
A. Chemical hazards present in liquids and vapors of electronic 
cigarettes. Arch Toxicol. 2014;88(7):1295‐1308.
 99. Kosmider L, Sobczak A, Prokopowicz A, et al. Cherry‐flavoured 
electronic cigarettes expose users to the inhalation irritant, benz-
aldehyde. Thorax. 2016;71(4):376‐377.
 100. Kim H‐J, Shin H‐S. Determination of tobacco‐specific nitrosa-
mines in replacement liquids of electronic cigarettes by liquid 
chromatography–tandem mass spectrometry. J Chromatogr A. 
2013;1291:48‐55.
 101. Farsalinos KE, Tsiapras D, Kyrzopoulos S, Savvopoulou M, 
Voudris V. Acute effects of using an electronic nicotine‐delivery 
device (electronic cigarette) on myocardial function: comparison 
with the effects of regular cigarettes. BMC Cardiovasc Disord. 
2014;14(1):78.
 102. Nguyen H, Kitzmiller J, Nguyen K, Nguyen C, Bui T. Oral car-
cinoma associated with chronic use of electronic cigarettes. 
Otolaryngol (Sunnyvale). 2017;7(304):2.
 103. Hureaux J, Drouet M, Urban T. A case report of subacute 
bronchial toxicity induced by an electronic cigarette. Thorax. 
2014;69(6):596‐597.
 104. Narang R, Narang D, Narang S, Salman J, Quyen N, Udeani G. 
Good, bad and ugly on vaping. Chest. 2015;148(4):385A.
 105. Itoh M, Aoshiba K, Herai Y, Nakamura H, Takemura T. Lung in-
jury associated with electronic cigarettes inhalation diagnosed by 
transbronchial lung biopsy. Respirol Case Rep. 2018;6(1):e00282.
 106. MacNee W. Oxidative stress and lung inflammation in airways 
disease. Eur J Pharmacol. 2001;429(1–3):195‐207.
 107. Redza‐Dutordoir M, Averill‐Bates DA. Activation of apoptosis 
signalling pathways by reactive oxygen species. Biochim Biophys 
Acta. 2016;1863(12):2977‐2992.
 108. Stämpfli MR, Anderson GP. How cigarette smoke skews immune 
responses to promote infection, lung disease and cancer. Nat Rev 
Immunol. 2009;9(5):377.
 109. Sopori M. Effects of cigarette smoke on the immune system. Nat 
Rev Immunol. 2002;2(5):372.
 110. Noguera A, Busquets X, Sauleda J, et al. Expression of adhesion 
molecules and G proteins in circulating neutrophils in chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med. 
1998;158(5):1664‐1668.
 111. McCauley L, Markin C, Hosmer D. An unexpected consequence 
of electronic cigarette use. Chest. 2012;141(4):1110‐1113.
How to cite this article: Chen I‐L, Todd I, Fairclough 
LC. Immunological and pathological effects of 
electronic cigarettes. Basic Clin Pharmacol Toxicol. 
2019;00:1–16. https://doi.org/10.1111/bcpt.13225
